|
HOME >>
Product
Developement Bulk
Drugs Under R&D
| |
Products Under
Development |
|
|
| |
|
Anti-Hypertensives |
Perindopril
Trandolapril
Cilazepril
|
|
Bronchodilators |
Loteprednol
Mometasone
Ciclesonide
Flumethasone
Desonide
|
|
|
Anti-Cancer |
Imatinib Mesylate
Capcetabine
Irenotican
|
|
Anti-Diabetic |
Glimepiride
|
|
Anti-Deprresents |
Ziprasidone
Aripiprazole
Zaleplon
Paroxetine HCL |
|
Taj Pharmaceuticals Ltd. recently announced its 2QFY04 results. On a YoY
basis, the company reported a strong 136% growth in topline and 33% growth
in bottomline. However, in view of the acquisitions in FY03, the two periods
are not comparable. Hence for our analysis, we have done a QoQ comparison.
Our
Customer Focus
With our expanding portfolio of advanced
products and services, and an organization built to provide product
development team support, taj is dedicated to assuring our customers'
success. Our products and
services
are designed to speed our customers’ products to market, increase efficiency
and reduce risk in their ongoing production. This customer focus has driven
our product, service and infrastructure evolution.
The focus is on using the most advanced
techniques in product identification and structure elucidation. Our
scientists have enabled us to develop processes for over 100 molecules.
Their talent and superior R&D skills have fuelled rapid process development
and reduction in product development time.

New
Developed Products
Oseltamivir Phosphate

Phenyl Propanolamine
Phenylephrine
Zolpidem Tartrate
Cisplatin [*]
Fluvoxamine Maleate [$]
Letrozole
Mometasone Furoate
Caffeine
[58-08-2]
|